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license (http://creativecognitive impairment and Alzheimer’s disease (AD). The present study aimed to examine serum in-
flammatory markers in preclinical stages of dementia and in AD, as well as to investigate their asso-
ciations with concomitant CeVD.
Methods: We performed a cross-sectional case–control study including 96 AD, 140 cognitively
impaired no dementia (CIND), and 79 noncognitively impaired participants. All subjects underwent
neuropsychological and neuroimaging assessments, as well as collection of blood samples for mea-
surements of serum samples interleukin (IL)-6, IL-8, and tumor necrosis factor a levels. Subjects
were classified as CIND or dementia based on clinical criteria. Significant CeVD, including white-
matter hyperintensities (WMHs), lacunes, and cortical infarcts, was assessed by magnetic resonance
imaging.
Results: After controlling for covariates, higher concentrations of IL-8, but not the other measured
cytokines, were associated with both CIND and AD only in the presence of significant CeVD (CIND
with CeVD: odds ratios [ORs] 4.53; 95% confidence interval [CI] 1.5–13.4 and AD with CeVD: OR
7.26; 95% CI 1.2–43.3). Subsequent multivariate analyses showed that among the types of CeVD
assessed, only WMH was associated with higher IL-8 levels in CIND and AD (WMH: OR 2.81;
95% CI 1.4–5.6).
Discussion: Serum IL-8 may have clinical utility as a biomarker for WMH in AD. Longitudinal
follow-up studies would help validate these findings.
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Alzheimer’s disease (AD), characterized by progressive
loss of memory and cognitive function, is the most com-
mon form of dementia in the elderly [1], and a majorimer’s Association. This is an open access article under the CC BY-NC-ND
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worldwide prevalence of AD will be quadruple that in
2006, which translates to 1 in every 85 people worldwide
having AD [2].
Originally regarded as an “immune privileged” organ,
the brain is now well known to exhibit key features of
inflammation. Accumulating evidence suggests that neuro-
inflammation plays an essential role in AD pathogenesis
[3], with alterations of brain cytokine levels reported
[4,5]. Furthermore, activated microglia and astrocytes as
well as increased concentrations of inflammatory
mediators have been detected in the vicinity of amyloid
plaques and neurofibrillary tangles in AD brain [3].
Indeed, meta-analyses of observational studies indicate a
significant association between the long-term use of
nonsteroidal anti-inflammatory drugs and lowered risk of
AD [6].
Neuroinflammation, when occurring in the acute phase
and resolved in a timely manner, is beneficial in combating
pathogens and in tissue repair. But a chronic neuroinflam-
matory response may contribute to neurodegeneration [7].
Cytokines released from such neuroinflammatory processes
are known to be mirrored in the periphery, thus allowing
measurements of potential biomarkers [8,9], which at
present include cerebrospinal fluid (CSF) markers
(combined phosphotau and b-amyloid 38/42) and
neuroimaging (hippocampal atrophy, amyloid positron
emission tomography) [10–12]. However, the invasiveness
and high costs associated with neuroimaging and CSF
investigations have hindered their wide clinical
application. In contrast, the minimal invasiveness and
relative low cost of blood-based investigations have stimu-
lated research into assessments of their feasibility as diag-
nostic and prognostic biomarkers. Indeed, several studies
of circulating cytokines have been reported (albeit with
inconsistent findings), with the majority of these studies
focused on staging after a diagnosis of dementia has
been made [4,5,13–16]. As neuroinflammation is thought
to be involved in disease pathogenesis in early stages, it
is important to also investigate inflammatory markers in
predementia stages such as mild cognitive impairment or
cognitive impairment no dementia (CIND), which are
associated with increased risk of AD but may also
represent better prospects for treatment and/or prevention
[17,18].
Besides b-amyloid mismetabolism and tau hyperphos-
phorylation, vascular disease has been suggested to play a
role in AD [19]. Several neuroimaging markers of cerebro-
vascular disease (CeVD), such as white-matter hyperinten-
sities (WMHs), cortical infarct, and lacunes, have been
shown to be associated with AD [20], and may exacerbate
the severity of dementia [21,22]. However, in previous
inflammatory marker studies, the impact of CeVD was
generally neglected. In this study, we aimed to measure
serum proinflammatory cytokines, including interleukin 6
(IL-6), IL-8, and tumor necrosis factor a (TNFa), in a mem-ory clinic cohort of CIND and AD who underwent neuroi-
maging assessments for CeVD.2. Methods
2.1. Study cohort
A case–control design was used. Cases (CIND and demen-
tia) with subjective complaints of memory loss and cognitive
impairment on neuropsychological assessmentwere recruited
from memory clinics from National University Hospital and
Saint Luke’s Hospital in Singapore. Controls were recruited
from both memory clinics and the community and were
defined as those with subjective memory impairment com-
plaints but who were cognitively normal on objective neuro-
psychological assessment. All subjects underwent clinical,
physical, and neuropsychological assessments and neuroi-
maging at the National University of Singapore from August
2010 till May 2014. Ethics approval for this study was ob-
tained from the National Healthcare Group Domain-
Specific Review Board (DSRB reference: 2010/00017; study
protocol number: DEM4233), and written informed consent
had been obtained from participants or their next-of-kin
before study recruitment and procedures. The study was con-
ducted in accordance with the Declaration of Helsinki.2.2. Questionnaires
Relevant demographic and medical information was
collected by administration of a detailed questionnaire. Data
collected included age, gender, education, marital status,
occupation, smoking, alcohol intake, ability to live indepen-
dently, handedness, previous head trauma, and family history
of dementia. Inquiries onmedical history included stroke, car-
diovascular diseases, hypertension, hyperlipidemia, diabetes
mellitus, vitamin B12 deficiency, thyroid disease, urinary,
and bowel incontinence, Parkinson disease, depressive symp-
toms, and psychiatric illnesses andwere subsequently verified
by review of the medical records. Barthel activities of daily
living indices were assessed for functional status.2.3. Neuroimaging
As previously described [23,24], a 3TSiemensMagnetom
Trio Tim scanner with a 32-channel head coil was used for
magnetic resonance imaging (MRI) at the Clinical Imaging
Research Center of the National University of Singapore.
CeVD was assessed using MRI markers for lacunes, cortical
infarcts, andWMHs. Briefly, the presence and quantification
of lacunes and cortical infarcts were defined on FLAIR and
T2 sequences using the STRIVE criteria [25], whereas
WMH grading was based on the Age-Related White Matter
Changes (ARWMC) scale [26]. Significant CeVD was
defined as the presence of cortical infarct and/or presence
of two or more lacunes, and/or confluent WMH (ARWMC
score 8) in two regions of the brain [23,24].
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Diagnosis of cognitive impairment and dementia were
made at weekly consensus meetings attended by clinicians
and neuropsychologists, where clinical histories, psycho-
metrics, and neuroimages were reviewed. CIND cases
were diagnosed by clinical judgment and further confirma-
tion by neuropsychological tests, namely, impairment in at
least one domain of the neuropsychological test battery con-
sisting of executive function, attention, language, visuomo-
tor speed, visuoconstruction, verbal memory, and visual
memory, in patients who did not meet the criteria for demen-
tia [23,24]. AD cases were diagnosed using the National
Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s disease and Related
Disorders Association criteria. Noncognitively impaired
(NCI) subjects were those assessed to be normal by
neuropsychological tests.Table 1
Demographic characteristics and inflammatory markers stratified by
baseline diagnosis
Characteristics
NCI,
n 5 79
CIND,
n 5 140
AD,
n 5 96 P-value
Age, year, mean (SD) 68.27 (6.0) 71.23 (8.1) 77.25 (7.3) ,.001*
Female, n (%) 41 (51.9) 67 (47.9) 60 (62.5) .08
Low education, n (%) 24 (30.4) 67 (47.9) 73 (76) ,.001y
APOE genotypez
APOE ε2 carrier, n (%) 8 (10.1) 16 (11.4) 16 (16.7) .36
APOE ε3 carrier, n (%) 76 (96.2) 134 (95.7) 88 (91.7) .312.5. Peripheral inflammatory markers
Nonfasting blood samples collected in serum-separating
tubes were centrifuged at 2000 rcf for 10 minutes at 4C,
after which aliquots of serum were mixed well and stored
at 280C until use. All samples were subject to only one
freeze-thaw cycle. Concentrations of interleukin 6 (IL-6),
IL-8, and TNFa were measured in duplicate by multiplex
xMAP-based Luminex assays (Millipore Corp., Billerica,
MA, USA) per manufacturer’s instructions. The detectable
concentration range of inflammatory markers is from 0.2
to 15,000 pg/mL (IL-6), 0.3 to 10,000 pg/mL (IL-8), and
0.3 to 10,000 pg/mL (TNFa).APOE ε4 carrier, n (%) 14 (17.7) 42 (30.0) 32 (33.3) .06
Diabetes mellitus, n (%) 17 (21.5) 53 (37.9) 44 (45.8) .003y
Hypertension, n (%) 43 (45.4) 96 (68.6) 81 (84.4) ,.001y
Hyperlipidemia, n (%) 53 (67.1) 106 (75.7) 70 (72.9) .39
Smoking, n (%) 18 (22.8) 42 (30.0) 27 (28.1) .51
Cardiovascular disease,
n (%)
4 (5.1) 23 (16.4) 18 (18.8) .02y
Inflammatory markers
IL-6, pg/mL, median
(range)
0.78 (11.9) 1.03 (45.3) 1.59 (59.8) .046x
IL-8, pg/mL, median
(range)
4.53 (12.2) 5.42 (20.2) 5.90 (44.8) ,.001k
TNFa, pg/mL,
median (range)
4.05 (12.9) 4.51 (15.2) 5.28 (16.6) .001{
Abbreviations: NCI, noncognitively impaired; CIND, cognitive impair-
ment no dementia; AD, Alzheimer’s disease; SD, standard deviation; IL,
interleukin; TNFa, tumor necrosis factor a; ANOVA, analysis of variance.
NOTE. Bold text indicates P values ,.05.
*Significant one-way ANOVAwith post hoc Bonferroni tests: NCI versus2.6. Covariates
Demographic information and information about risk fac-
tors such as hypertension, hyperlipidemia, diabetes, smok-
ing, and cardiovascular diseases were collected from
physical and clinical interview andmedical records and clas-
sified as absent or present. Hypertension was defined as sys-
tolic blood pressure 140 mmHg and/or diastolic blood
pressure90 mmHg or use of antihypertensive medications.
Cardiovascular diseases were classified as a previous history
of atrial fibrillation, congestive heart failure, and/or myocar-
dial infarction. Apolipoprotein E (APOE) genotyping using
DNA extracted from the buffy coat of blood samples were as
previously described [27] for the determination of APOE ε4
carrier status (presence of at least one APOE ε4 allele).CIND, P 5 .01; NCI versus AD, P , .001; CIND versus AD, P , .001.
ySignificant chi-square tests.
zAPOE genotype: APOE ε2, APOE ε3, APOE ε4 carrier denotes presence
of at least one APOE ε2, APOE ε3, or APOE ε4 alleles, respectively.
xSignificant Kruskal–Wallis ANOVA with post hoc Dunn’s tests: NCI
versus AD, P 5 .02.
kSignificant Kruskal–Wallis ANOVA with post hoc Dunn’s tests: NCI
versus CIND, P , .01; NCI versus AD, P , .001.
{Significant Kruskal–Wallis ANOVA with post hoc Dunn’s tests: NCI
versus AD, P 5 .001.2.7. Statistical analyses
Statistical analysis was performed using SPSS software
(version 21, IBM Inc., Armonk, NY, USA). For group com-
parisons, one-way analyses of variance (ANOVAs) were
used for normally distributed continuous variables (age);
chi-square tests for categorical variables (gender, education,
APOE ε4, hypertension, hyperlipidemia, smoking, diabetes,cardiovascular disease); nonparametric Kruskal–Wallis
ANOVAwith Dunn’s post hoc were used for skewed distrib-
uted continuous variables (inflammatory markers). Binary
logistic regression was used to assess the association
between inflammatory markers and primary diagnosis
(NCI, CIND, or AD). The levels of inflammatory markers
were included as determinants in the logistic models and
were categorized into tertiles, whereas CIND and AD were
listed as outcomes. Odds ratios and 95% confidence intervals
were reported for both CIND and AD. All the models were
adjusted for age, gender, education, APOE ε4 carrier status,
diabetes mellitus, hypertension, and cardiovascular diseases.
A P-value of ,.05 was considered statistically significant
for all analyses.3. Results
A total of 383 elderly subjects (95 NCI, 164 CIND, 124
AD) were recruited, of whom 315 (79 NCI, 140 CIND,
and 96 AD) had available blood samples and MRI data. Of
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(55.2%) subjects had significant CeVD on MRI. Table 1
shows the demographic variables of the study cohort. In
comparison to NCI, CIND and ADwere older, had lower ed-
ucation levels, higher prevalence of diabetes, hypertension,
and cardiovascular disease. The concentration values of in-
flammatory markers in the samples ranged from 0.3 to
60.0 pg/mL for IL-6, 1.3 to 47.0 pg/mL for IL-8, and 0.9
to 17.5 pg/mL for TNFa. The lowest detectable values
were used in statistical analyses for cases whose concentra-
tions fell below detectable range (0.2 pg/mLwas used for IL-
6 for 28 cases in NCI group, 50 cases in CIND group, and 20
cases in AD group; 0.3 pg/mL was used for TNFa for two
cases in NCI group and 1 case in CIND group). As shown
in Table 1, levels of IL-6, IL-8, and TNFa were highest in
AD and lowest in NCI, with intermediate levels in CIND.
The differences were statistically significant for IL-8 in
both CIND and AD, whereas IL-6 and TNFa were signifi-
cantly raised only in AD.
Table 2 shows the multivariate analyses of associations
between serum inflammatory markers and clinical diagno-
ses. There was no association between IL-6 and CIND or
AD after adjustment for covariates of age, gender, education,
APOE ε4 carrier, diabetes mellitus, hypertension, and car-
diovascular diseases, whereas the highest tertile of IL-8
was associated with CIND and AD. In contrast, the highest
tertile of TNFa was associated with AD but not CIND
when unadjusted (data not shown), but the association did
not remain after adjusting for covariates. Interestingly,
when stratified by the presence or absence of significant
CeVD (Table 3), the highest tertile of IL-8 was associated
with both CIND and AD only in the presence of CeVD,
whereas no associations were found for IL-6 and TNFa in
the presence or absence of CeVD. Finally, to uncoverTable 2
Association of inflammatory markers (in tertiles) with CIND and AD,
expressed as odds ratios with 95% confidence intervals
Inflammatory
markers
CIND odds ratio
(95% CI)*
AD odds ratio
(95% CI)*
IL-6
1st tertile 1 1
2nd tertile 0.72 (0.4–1.5) 1.29 (0.5–3.6)
3rd tertile 0.95 (0.5–2.0) 1.15 (0.4–3.4)
IL-8
1st tertile 1 1
2nd tertile 0.81 (0.4–1.6) 0.57 (0.2–1.6)
3rd tertile 2.80 (1.2–6.7) 2.41 (0.7–8.9)
TNFa
1st tertile 1 1
2nd tertile 1.27 (0.6–2.7) 1.00 (0.3–2.9)
3rd tertile 1.17 (0.5–2.5) 1.23 (0.4–3.6)
Abbreviations: CIND, cognitive impairment no dementia; AD, Alz-
heimer’s disease; CI, confidence interval; IL, interleukin; TNFa, tumor ne-
crosis factor a.
NOTE. N values for CIND5 140; AD5 96. Bold text indicates P values
,.05.
*Adjusted for age, gender, education, APOE ε4 carrier, diabetes mellitus,
hypertension, and cardiovascular diseases.whether IL-8 was associated with a specific type of CeVD,
we performed separate logistic regression analyses for
WMH, presence of cortical infarcts and lacunes with adjust-
ment for unmatched demographic and risk factors, as well as
the corresponding nontested MRI markers. Table 4 shows
the association between the highest tertile of IL-8 and
MRI markers was with WMH (ARWMC total score  8),
but not with presence of cortical infarct nor lacunes (two
or more).4. Discussion
Although all three inflammatory markers (IL-6, IL-8, and
TNFa) were found to be significantly different among NCI,
CIND, and AD patients, only elevated IL-8 was associated
with CIND and AD after adjustment for age, gender, educa-
tion, APOE ε4 carrier, diabetes mellitus, hypertension, and
cardiovascular diseases. Furthermore, the associations with
IL-8 were significant only in the presence of CeVD, and
more specifically, with the presence of WMH when adjusted
for covariates.
IL-8 (also known as CXCL8) is a chemokine which in-
duces chemotaxis in target cells, migrating neutrophils, ba-
sophils, and T cells to the site of infection [28]. In this
study, we found that high-serum IL-8 was associated with
both CIND and AD only in the presence of CeVD, specif-
ically with significant WMH, independent of age, gender,
education, APOE ε4 carrier status, diabetes mellitus, hyper-
tension, cardiovascular diseases, as well as cortical infarct
and lacunes. This finding corroborates previous work
showing high IL-8 in cognitively impaired patients associ-
ated with vascular cognitive impairment [29]. IL-8 has
been known to initiate acute inflammation, and our data sup-
port the involvement of elevated IL-8 in the chronic neuro-
inflammation of AD which may be related to
cerebrovascular damage [30]. Actually, significant eleva-
tions in plasma IL-8 levels in cognitive impairment have
also been reported by others [5,13], although there are also
conflicting data showing lower IL-8 level in mild cognitive
impairment and AD [31]. The mechanism underlying asso-
ciations of IL-8 withWMH is at present unclear. The disease
processes may be related to microglial activation-associated
upregulation of cytokines besides inducible nitric oxide syn-
thase [32], which in turn trigger increases in proinflamma-
tory and pro-oxidant nitric oxide, affect brain microvessel
endothelia, and result in white-matter lesions detectable as
WMH by MRI [33,34]. Although these lesions have been
shown to be associated with, and predict for, cognitive
impairment [35–37], whether such processes actually link
IL-8 with white-matter lesions will require follow-up
studies.
IL-6 can be produced by a variety of immune cells as
well as endothelial cells and fibroblasts and is a primary
inducer of acute proteins and hormones which mediate fe-
ver and immune cell expansion in response to infection or
injury [28]. Interestingly, IL-6 also has anti-inflammatory
Table 3
Associations of inflammatory markers with CIND and AD stratified by the presence of CeVD, expressed as odds ratios with 95% confidence intervals
Inflammatory markers
With CeVD* Without CeVD*
CIND odds ratio (95% CI) AD odds ratio (95% CI) CIND odds ratio (95% CI) AD odds ratio (95% CI)
IL-6
1st tertile 1 1 1 1
2nd tertile 0.73 (0.3–1.8) 0.84 (0.2–3.4) 0.65 (0.3–1.6) 2.12 (0.6–7.7)
3rd tertile 0.89 (0.4–2.1) 0.96 (0.3–3.6) 0.86 (0.4–2.1) 1.14 (0.3–4.6)
IL-8
1st tertile 1 1 1 1
2nd tertile 1.00 (0.4–2.4) 0.31 (0.1–1.5) 0.58 (0.3–1.3) 0.74 (0.2–2.6)
3rd tertile 4.53 (1.5–13.4) 7.26 (1.2–43.3) 1.99 (0.7–5.4) 1.09 (0.2–5.7)
TNFa
1st tertile 1 1 1 1
2nd tertile 1.17 (0.5–2.9) 0.86 (0.2–3.6) 1.31 (0.6–3.0) 0.99 (0.3–3.7)
3rd tertile 1.42 (0.6–3.5) 1.32 (0.3–5.6) 1.00 (0.4–2.5) 1.12 (0.3–4.3)
Abbreviations: CIND, cognitive impairment no dementia; AD, Alzheimer’s disease; CeVD, cerebrovascular disease; CI, confidence interval; IL, interleukin;
TNFa, tumor necrosis factor a.
NOTE. N values for CIND with CeVD 5 68; AD with CeVD 5 53. Bold text indicates P values ,.05.
*Adjusted for age, gender, education, APOE ε4 carrier, diabetes mellitus, hypertension, and cardiovascular diseases.
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flicting results where a few studies have shown increased
levels of serum or plasma IL-6 levels in AD [4,15],
whereas other studies reported unchanged peripheral
levels of IL-6 between control, mild cognitive impairment,
and AD [14,39–41]. In the present study, although higher
IL-6 was found in AD, subsequent multivariate analyses
did not support associations of serum IL-6 with AD or
concomitant CeVD.
TNFa is a proinflammatory cytokine, produced primarily
by activated macrophages, T cells, and NK cells. It is a medi-
ator of both acute and chronic inflammation and can activate
vascular endothelium and increase vascular permeability
[28]. Similar to the other markers, there are inconsistent re-
sults on the status of peripheral TNFa in AD with reports
of significantly lower [14,42], unchanged [43,44], or
increased [45,46] TNFa in mild cognitive impairment and/
or AD. The present study showed that, like the other two
markers, serum TNFa was increased in AD, although the
association was not statistically significant when adjusted
for covariates. This suggests confounding by concomitant
risk factors. Indeed, there is evidence of TNFa involvementTable 4
Associations of IL-8 (in tertiles) with MRI markers of CeVD, expressed as odds
Inflammatory marker WMH (ARWMC  8), odds ratio (95% CI)* Co
IL-8
1st tertile 1 1
2nd tertile 1.28 (0.7–2.5) 2.1
3rd tertile 2.81 (1.4–5.6) 3.5
Abbreviations: IL, interleukin; MRI, magnetic resonance imaging; CeVD, cer
related white-matter changes; CI, confidence interval; CIND, cognitive impairme
NOTE. N values for CIND with CeVD 5 68; AD with CeVD 5 53. N values f
(2) 5 37. Bold text indicates P values ,.05.
*Adjusted for age, gender, education, APOE ε4 carrier, hypertension, diabetes
yAdjusted for age, gender, education, APOE ε4 carrier, hypertension, diabetes
zAdjusted for age, gender, education, APOE ε4 carrier, hypertension, diabetesin cardiovascular disease [47–49] which was included as a
covariate in our study.
The strengths of this study include the following: (1) a
relatively large cohort; (2) inclusion of covariates such as
age, gender, education, APOE ε4 carrier status, diabetes
mellitus, hypertension, and cardiovascular diseases in ana-
lyses; and (3) use of neuroimaging to classify cases with
CeVD and hence allowing the assessment of CeVD impact.
However, our study has several limitations as well. First,
because of the case–control design of the study, it is not
possible to establish the temporal association between
these markers and the development of cognitive impair-
ment. Further follow-up prospective validation studies
will address these limitations. Furthermore, the cases and
controls, though representative of the elderly population
in Singapore, were derived from two settings, that is, mem-
ory clinic and community. Finally, the control group was
relatively younger and had lower CeVD burden compared
to cases which could have resulted in selection bias and re-
sidual confounding.
In conclusion, the present study suggests that IL-8 has po-
tential clinical utility as a biomarker of small vessel CeVDratios with 95% confidence intervals
rtical infarct, odds ratio (95% CI)y 2 lacunes, odds ratio (95% CI)z
1
0 (0.6–7.6) 0.94 (0.3–3.2)
0 (0.9–13.1) 2.70 (0.9–8.4)
ebrovascular disease; WMH, white-matter hyperintensity; ARWMC, age-
nt no dementia.
or significant WMH (ARWMC  8) 5 118, cortical infarcts 5 28, lacunes
mellitus, cardiovascular diseases, presence of cortical infarct, and lacunes.
mellitus, cardiovascular diseases, WMH, and presence of lacunes.
mellitus, cardiovascular diseases, WMH, and presence of cortical infarct.
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follow-up longitudinal studies are needed for validation.
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1. Systematic review: Although neuroinflammation is
widely considered to play a pathogenic role in Alz-
heimer’s disease (AD), the extent to which changes
in peripheral inflammatory markers may reflect
concomitant cerebrovascular disease (CeVD) has not
been studied in either cognitive impairments no de-
mentia (CIND), a predementia stage, or inAD, despite
evidence in the literature indicating the exacerbating
effects of concomitant CeVD on dementia severity.
2. Interpretation: Of the three acute inflammatory
markers investigated, only elevated IL-8 was asso-
ciated with white-matter hyperintensities in CIND
and AD, suggesting that interleukin-8 is a potential
biomarker for small vessel CeVD in cognitive
impairment and AD.
3. Future directions: A case–control design was used
for our study. Follow-up longitudinal studies are
needed for validation.References
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